StudyFinder

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]

Status: Recruiting

This research study is testing whether a medication called pelacarsen can help slow the worsening of calcific aortic valve stenosis (CAVS), a heart valve disease that currently has no proven medication treatment. The study includes people with mild to moderate CAVS and high Lp(a) levels, which may increase disease progression, and compares the medication to a placebo.

I'm interested

Sex: Male or Female
Age: 18 years and over
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Age equal or more than 50 and less than 80
• Lp(a) equal or more than 175 nmol/L
• Mild or moderate aortic valve stenosis
Exclusion Criteria:

• Severe aortic valve stenosis
• Significant additional disease/conditions such as cancer, severe liver or kidney disease, etc.
Interventions:

Drug/Device: Pelacarsen

Conditions:

Elevated Lipoprotein(a) and Aortic Valve Stenosis

Keywords:

Aortic Valve, Lipoprotein(a)

Contact(s): Jodi Carter - GeneralCardiologyResearch@hfhs.org
Principal Investigator: Khaled Nour
Principal Investigator ID: knour1@hfhs.org
Phase: II
See this study on ClinicalTrials.gov

Back